16 research outputs found
Adenoid cystic carcinoma of the peripheral lung: a case report
Adenoid cystic carcinoma of the peripheral lung is a rare entity. We recently encountered a patient with adenoid cystic carcinoma. A 75-year-old woman showed a nodular lesion with 10 mm in diameter in the right upper lung field on chest radiography. The diagnosis was unclear, but lung cancer could not be ruled out. Thoracoscopic biopsy was performed, and intraoperative pathological diagnosis revealed the carcinoma of the lung. We enforced upper lobectomy and mediastinal lymph node dissection to the patient. Histopathological examination revealed adenoid cystic carcinoma with a characteristic cribriform structure. Immunohistochemical examination revealed that the tumor cells were positive for thyroid transcription factor 1 (TTF-1), this tumor was diagnosed primary ACC of the lung
Infrequent RAS mutation is not associated with specific histological phenotype in gliomas
BACKGROUND: Mutations in driver genes such as IDH and BRAF have been identified in gliomas. Meanwhile, dysregulations in the p53, RB1, and MAPK and/or PI3K pathways are involved in the molecular pathogenesis of glioblastoma. RAS family genes activate MAPK through activation of RAF and PI3K to promote cell proliferation. RAS mutations are a well-known driver of mutation in many types of cancers, but knowledge of their significance for glioma is insufficient. The purpose of this study was to reveal the frequency and the clinical phenotype of RAS mutant in gliomas. METHODS: This study analysed RAS mutations and their clinical significance in 242 gliomas that were stored as unfixed or cryopreserved specimens removed at Kyoto University and Osaka National Hospital between May 2006 and October 2017. The hot spots mutation of IDH1/2, H3F3A, HIST1H3B, and TERT promoter and exon 2 and exon 3 of KRAS, HRAS, and NRAS were analysed with Sanger sequencing method, and 1p/19q codeletion was analysed with multiplex ligation-dependent probe amplification. DNA methylation array was performed in some RAS mutant tumours to improve accuracy of diagnosis. RESULTS: RAS mutations were identified in four gliomas with three KRAS mutations and one NRAS mutation in one anaplastic oligodendroglioma, two anaplastic astrocytomas (IDH wild-type in each), and one ganglioglioma. RAS-mutant gliomas were identified with various types of glioma histology. CONCLUSION: RAS mutation appears infrequent, and it is not associated with any specific histological phenotype of glioma
Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2
金沢大学がん研究所分子標的がん医療研究開発センターLysophosphatidic acid (LPA) is one of the simplest natural phospholipids. This phospholipid is recognized as an extracellular potent lipid mediator with diverse effects on various cells. Although LPA is shown to stimulate proliferation and motility via LPA receptors, LPA1 and LPA2, in several cancer cell lines, the role of LPA and LPA receptors for malignant pleural mesothelioma (MPM) has been unknown. MPM is an aggressive malignancy with a poor prognosis and the incidence is increasing and is expected to increase further for another 10-20 years worldwide. Therefore, the development of novel effective therapies is needed urgently. In this study, we investigated the effect of LPA on the proliferation and motility of MPM cells. We found that all 12 cell lines and four clinical samples of MPM expressed LPA1, and some of them expressed LPA2, LPA3, LPA4 and LPA5. LPA stimulated the proliferation and motility of MPM cells in a dose-dependent manner. Moreover, LPA-induced proliferation was inhibited by Ki16425, an inhibitor of LPA1, and small interfering RNA against LPA1, but not LPA2. Interestingly, LPA-induced motility was inhibited by small interfering RNA against LPA2, but not LPA1, unlike a number of previous reports. These results indicate that LPA is a critical factor on proliferation though LPA1, and on motility though LPA2 in MPM cells. Therefore, LPA and LPA receptors, LPA2 as well as LPA1, represent potential therapeutic targets for patients with MPM. © 2008 Japanese Cancer Association
Analysis of DOC and Ram for NSCLC
Background: Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared to chemotherapy alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, the combination therapy of docetaxel (Doc) and ramucirumab (Ram) was considered one of the standard treatments for advanced or relapsed NSCLC patients. However, little is known about the therapeutic responders of this combination therapy among previously treated NSCLC patients. In the present study, we aimed to identify predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for Doc treatment in combination with Ram.
Methods: We retrospectively analyzed a total of 135 advanced or relapsed NSCLC patients who were refractory to platinum-based chemotherapy at eleven institutions in Japan between July 2016 and November 2018.
Results: Our observations showed that PD-L1 expression in tumors is not associated with the efficacy of combined therapy of Doc and Ram in previously treated NSCLC patients. Analysis of the patient clinical profiles indicated that prior treatment with immune checkpoint inhibitors (ICIs) is a reliable predictor for the good progression-free survival (PFS) to this combination therapy (P=0.041).
Conclusions: Our retrospective study indicated that combination regimens comprising chemotherapy and ICIs followed by Doc and Ram could be an optimal therapeutic option for NSCLC patients regardless of the PD-L1 status of tumors. Further investigations are required to strengthen clinical evidence demonstrating the effectiveness of the combination therapy of Doc plus Ram in previously treated NSCLC patients
Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital
Platinum-doublet regimens and docetaxel as first- and second-line chemotherapy,
respectively, are shown to prolong the survival of lung cancer patients in various
randomized phase III studies. However, the evidence for the efficacy of chemotherapy
for lung cancer in the clinical practice is still insufficient. In the present study, we
investigated the effectiveness and safety of outpatient chemotherapy for lung cancer in
the clinical practice. Ninety-four lung cancer cases were retrospectively analyzed. Among
these cases, 67 (71.3%) were non-small cell lung cancer (NSCLC) and 27 (28.7%) were
small cell lung cancer (SCLC). The response rates in SCLC and NSCLC patients were
55.6% (15/27) and 16.9% (11/65), respectively. Objective tumor response rates for the patients
were found to decrease substantially with each line of treatment as described previously.
All adverse events were well tolerated and no treatment-related death was observed.
Median time to treatment failures (TTFs) of first-line treatment were 10.1 months
and 4.8 months in SCLC and NSCLC, respectively. These findings indicate that even in
the setting of clinical practice, the efficacy and safety of chemotherapy is strictly insured
by the appropriate therapeutic management
Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan
Lung cancer is the leading cause of malignancy-related death worldwide. In
the present study, we reviewed the epidemiologic and clinical features of lung cancer in
Tokushima Prefecture, Japan. Between January 1999 and December 2009, 2,183 patients
with lung cancer were enrolled in this study. One thousand five hundred ninety-one (73%)
patients were male and 592 (27%) patients were female. Median age was 70 years, with a
range of 15-93 years. Seventy-six percent of patients had smoking history. One thousand
nine hundred five (87%) patients were non-small cell lung cancer and the predominant histological
type was adenocarcinoma (51%). Among all 2,183 patients, 702 (32%) belonged to
elderly population. Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%),
370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, respectively.
In Tokushima University Hospital, 516 (29%), 191 (11%), 58 (3%), 755 (43%) and
216 (12%) patients were initially treated with chemotherapy, chemo-radiotherapy, thoracic
radiotherapy, operation and best supportive care, respectively. The median time to
progression (TTP) and the median survival time (MST) of patients treated with chemotherapy
and chemo-radiotherapy were 3.5 months, 13.0 months and 7.0 months, 18.0 months,
respectively. The median TTP and the MST of 33 elderly patients treated with chemotherapy
were 3.3 months and 18.0 months, respectively, which were comparable with those of
total population. These results indicated the benefit of chemotherapy in elderly patients
with advanced lung cancer by proper selection